Positron Emission Tomography in Diagnosis and Management of Invasive Breast Cancer: Current Status and Future Perspectives

https://doi.org/10.3816/CBC.2003.s.016Get rights and content

Abstract

[18F]fluorodeoxyglucose positron emission tomography (FDG-PET) is a metabolic imaging modality that has increasing applications in oncology, neurology, and cardiology. Among the oncology applications, breast cancer is one of the most extensively studied diseases. FDG-PET has been performed for diagnosis, staging, and restaging of invasive breast cancer and for monitoring responsiveness to therapies. At the present time, the results of FDG-PET in detection of primary breast cancer and axillary staging are mixed and inconclusive. However, results demonstrating the superiority of FDG-PET over anatomic imaging modalities in detection of distant metastasis, recurrence, and monitoring therapies are relatively well documented. These applications have been accepted by medical professionals and the public, as evidenced by a recent decision by the Centers for Medicare & Medicaid Services (formerly Health Care Financing Agency) to provide coverage for the procedure. Future trends in this exciting area include development of novel breast cancer—specific PET radiopharmaceuticals and use of dedicated breast PET technologies for scans of breast/axillary lesions. PET/computed tomography technology, which combines anatomic and molecular/biochemical information, is also rapidly proliferating and should help to further improve the management of patients with breast cancer. The role of FDG-PET in breast cancer is increasing and evolving, and this metabolic imaging modality, in conjunction with newer tracers and other anatomic imaging methods, should improve diagnosis and management of patients with breast cancer.

References (73)

  • SS Gambhir et al.

    A tabulated summary of the FDG PET literature

    J Nucl Med

    (2001)
  • CS Yap et al.

    Impact of whole-body 18F-FDG PET on staging and managing patients with breast cancer: the referring physician's perspective

    J Nucl Med

    (2001)
  • ME Phelps et al.

    Application of annihilation coincidence detection to transaxial reconstruction tomography

    J Nucl Med

    (1975)
  • SS Gambhir

    Molecular imaging of cancer with positron emission tomography

    Nat Rev Cancer

    (2002)
  • N Avril et al.

    Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations

    J Clin Oncol

    (2000)
  • RL Wahl et al.

    Primary and metastatic breast carcinoma: initial clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy-D-glucose

    Radiology

    (1991)
  • NY Tse et al.

    The application of positron emission tomographic imaging with fluorodeoxyglucose to the evaluation of breast disease

    Ann Surg

    (1992)
  • EU Nitzsche et al.

    [Whole body positron emission tomography in breast cancer]

    Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr

    (1993)
  • OE Nieweg et al.

    Positron emission tomography with fluorine-18-deoxyglucose in the detection and staging of breast cancer

    Cancer

    (1993)
  • LP Adler et al.

    Evaluation of breast masses and axillary lymph nodes with [F-18] 2-deoxy-2-fluoro-D-glucose PET

    Radiology

    (1993)
  • JP Crowe et al.

    Positron emission tomography and breast masses: comparison with clinical, mammographic, and pathological findings

    Ann Surg Oncol

    (1994)
  • N Avril et al.

    Metabolic characterization of breast tumors with positron emission tomography using F-18 fluorodeoxyglucose

    J Clin Oncol

    (1996)
  • K Scheidhauer et al.

    Qualitative [18F]FDG positron emission tomography in primary breast cancer: clinical relevance and practicability

    Eur J Nucl Med

    (1996)
  • K Yutani et al.

    Detectability of FDG-PET and MIBI-SPECT to breast cancer [abstract]

    J Nucl Med

    (1997)
  • H Palmedo et al.

    Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and technetium-99m methoxyisobutylisonitrile scintimammography in the detection of breast tumours

    Eur J Nucl Med

    (1997)
  • DY Noh et al.

    Diagnostic value of positron emission tomography for detecting breast cancer

    World J Surg

    (1998)
  • K Yutani et al.

    Effect of patients' being prone during FDG PET for the diagnosis of breast cancer

    AJR Am J Roentgenol

    (1999)
  • H Fuji et al.

    The usefulness of breast cancer screening using 18F FDG PET [abstract]

    J Nucl Med

    (2000)
  • K Yutani et al.

    Comparison of FDG-PET with MIBISPECT in the detection of breast cancer and axillary lymph node metastasis

    J Comput Assist Tomogr

    (2000)
  • H Schirrmeister et al.

    Fluorine-18 2-deoxy-2-fluoro-D-glucose PET in the preoperative staging of breast cancer: comparison with the standard staging procedures

    Eur J Nucl Med

    (2001)
  • F Crippa et al.

    Prospective evaluation of fluorine-18-FDG PET in presurgical staging of the axilla in breast cancer

    J Nucl Med

    (1998)
  • R Bos et al.

    Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography

    J Clin Oncol

    (2002)
  • KR Zasadny et al.

    FDG metabolism and uptake versus blood flow in women with untreated primary breast cancers

    Eur J Nucl Med Mol Imaging

    (2003)
  • V Bernstein et al.

    Assessment of internal mammary lymph nodes by fluorodeoxyglucose positron emission tomography (FDG-PET) in medial hemisphere breast cancer [abstract]

    J Nucl Med

    (2000)
  • JS Meyer

    Sentinel lymph node biopsy: strategies for pathologic examination of the specimen

    J Surg Oncol

    (1998)
  • U Guller et al.

    Selective axillary surgery in breast cancer patients based on positron emission tomography with 18F-fluoro-2-deoxy-D-glucose: not yet!

    Breast Cancer Res Treat

    (2002)
  • Cited by (46)

    • Imaging

      2019, Abeloff’s Clinical Oncology
    • Phase II study of liposome-encapsulated doxorubicin plus cyclophosphamide, followed by sequential trastuzumab plus docetaxel as primary systemic therapy for breast cancer patients withHER2 overexpression or amplification

      2013, Breast
      Citation Excerpt :

      However, FDG-PET is superior compared to CT scan in detection of internal mammary and mediastinal lymph nodes [22]. Sensitivity, specificity and accuracy for internal mammary and mediastinal lymph nodes were 85%, 90% and 88% respectively for FDG-PET, compared to 54%, 85% and 73% respectively for CT scan [23]. FDG-PET may provide additional information in early stages of breast cancer.

    • Imaging

      2013, Abeloff's Clinical Oncology: Fifth Edition
    • FDG-PET Dynamic Contrast-Enhanced CT in the Management of Breast Cancer

      2009, PET Clinics
      Citation Excerpt :

      For breast cancer, FDG-PET often shows locoregional or unsuspected distant disease and is particularly helpful for evaluating chemotherapy response in patients who have locally advanced breast carcinoma and those who have metastatic disease.12 Whole body FDG-PET can provide functional information that is not provided by anatomic imaging modalities such as CT or mammography, and can help narrow the differential diagnosis of breast masses, stage the cancer, and monitor patients posttreatment.9,13 FDG-PET has an important role in predicting tumor response in patients who have locally advanced breast cancer undergoing neoadjuvant chemotherapy, and differentiating scar tissue from cancer recurrence.9,14

    • Dual time point FDG-PET/CT imaging... Potential tool for diagnosis of breast cancer

      2008, Clinical Radiology
      Citation Excerpt :

      The majority of FDG-PET research studies have been performed on patients with invasive breast cancer. In a meta-analysis, Wu and Gambhir33 reported that the overall sensitivity, specificity, and accuracy of FDG-PET in the detection of primary invasive breast cancer are 90, 92, and 93%, respectively. In a large study of single-phase PET for beast tumour imaging, Avril et al.,32 found that the major limitation was a poor detection rate for small (pT1a and pT1b) breast carcinomas.

    View all citing articles on Scopus
    View full text